As a development-stage biopharmaceutical company, we incurred negative cash flows from our operations during the Track Record Period.
Financial Information · p. 481
During the Track Record Period, our primary uses of cash were to fund the development of our drug pipeline, clinical trials, procurement of services, payment for the purchase of plant and equipment, administrative expenses and other recurring expenses.
Financial Information · p. 481
we will have sufficient working capital to cover at least 125% of our costs, including research and development costs and administrative expenses, for at least the next twelve months from the date of this prospectus
We had negative operating cash flows during the Track Record Period.
Summary · p. 24
Based on the cash and cash equivalents on hand, our operating cash flows, the available financing facilities, and the estimated net proceeds available to us from the Global Offering, our Directors are of the view, and the Joint Sponsors concur, that we have sufficient working capital for our present requirements and for at least the next 12 months from the date of this prospectus.
Summary · p. 24
We expect to record net profit and net operating cash inflow in the near future.
With a thin profit margin, we would record net cash used in operating activities when we have negative movement in our working capital (including inventories, trade and bills receivables and trade and bills payables) outweighing our operating profit.
Summary · p. 7
For instance, we had net cash used in operating activities of approximately RMB45.8 million, RMB11.1 million and RMB10.6 million for FY2021, 9M2023 and 9M2024, respectively, which were mainly driven by negative working capital movement outweighing our operating profit.
We recorded net cash used in operating activities of RMB52.7 million, RMB113.9 million, RMB314.3 million, RMB126.2 million and RMB134.1 million in 2021, 2022, 2023 and the six months ended June 30, 2023 and 2024, respectively.
Summary · p. 18
Our operating cash outflow is mainly due to increases in our trade and other receivables during the same periods as a result of increases in the sales of our products and services and the longer payment cycles of certain regional healthcare administrator customers.
Business · p. 237
Our Directors are of the view, and the Joint Sponsors concur, that we have sufficient working capital required for our operations at present and for at least the next 12 months from the date of this prospectus based on our cash flow projections and taking into account our business operations as well as the financial resources available to us, including our cash and cash equivalents, unutilized banking facilities and estimated net proceeds from the Global Offering.
Our net cash used in operating activities amounted to RMB562.1 million, RMB936.3 million, RMB593.6 million, RMB240.9 million and RMB155.5 million, respectively, in 2021, 2022, 2023 and the six months ended June 30, 2023 and 2024.
Summary · p. 2
Our net cash used in operating activities experienced significant improvements, decreasing from RMB936.3 million in 2022 to RMB593.6 million in 2023, and from RMB240.9 million in the six months ended June 30, 2023 to RMB155.5 million in the six months ended June 30, 2024.
Business · p. 291
With our expecting business scale, growing economies of scale, improving operating efficiency and more effective management of our working capital, we expect a further improvement in our operating cash flow, leading to net operating cash inflow in the near future.
We recorded net operating cash outflows in 2021, 2022, 2023 and the five months ended May 31, 2024, primarily due to (i) the significant operating expenses incurred to support our business development. These expenses encompassed various aspects, including the purchase of raw materials for our productions, research and development expenditures to enhance our R&D capabilities, selling and marketing expenses, and administrative expenses to support the development and promotion of our products; and (ii) the prolonged settlement of trade receivables.
Summary · p. 22
As of September 30, 2024, we had unutilized banking facilities of RMB348.4 million, which were committed and unrestricted.
Business · p. 345
Our Directors are of the view that we have sufficient working capital to support our business operations up to 2026, even without the net proceeds from the Global Offering, after taking into account our existing cash and cash equivalents, unutilized banking facilities and our ability to obtain additional banking facilities, supply chain financing and/or other equity financing when necessary.
Our net cash used in operating activities were RMB1,274.7 million, RMB205.5 million, RMB179.2 million and RMB56.7 million for the years ended December 31, 2021, 2022, and 2023 and the six months ended June 30, 2024, respectively.
Summary · p. 13
Despite experiencing a net operating cash outflow in the Track Record Period, we anticipate an improvement in our operating cash flow as we expect to improve our loss making position gradually.
We recorded net cash used in operating activities of RMB254.4 million and RMB173.9 million in 2021 and 2022, respectively, and realized net operating cash inflow of RMB8.4 million in 2023.
Business · p. 239
We believe that our current financial resources are sufficient to cover the net cash flows used in our operating activities to provide sufficient liquidity for our continuing business operations.
We recorded net cash used in operating activities of RMB79.4 million, RMB149.3 million, RMB69.1 million and RMB51.0 million for the years ended December 31, 2022 and 2023 and the five months ended May 31, 2023 and 2024, respectively.
Financial Information · p. 471
During the Track Record Period, we financed our operations primarily through equity financing.
Financial Information · p. 471
Our Directors are of the view that, taking into account the financial resources available to us, including cash and cash equivalents and the estimated net proceeds from the Global Offering, and considering our cash burn rate, we have sufficient working capital to cover at least 125% of our costs, including cost of sales, selling and distribution expenses, R&D expenses and administrative expenses for at least the next 12 months from the expected date of this prospectus.
We had net operating cash outflow of RMB1,111.0 million, RMB1,557.3 million, RMB1,744.5 million, RMB1,166.0 million and RMB726.0 million in 2021, 2022 and 2023, and for the six months ended June 30, 2023 and 2024, respectively
Summary · p. 27
Our total cash balance is sufficient to cover our cash needs for operating activities and provides adequate liquidity for our expansion and growth strategies.
In addition, we experienced net cash flows used in our operating activities of RMB217.5 million, RMB329.2 million and RMB351.2 million and RMB112.6 million for 2021, 2022, 2023 and the three months ended March 31, 2024, respectively.
Summary · p. 10
The reasons of our cash flows used in our operating activities in 2023 and the three months ended March 31, 2024 primarily include our loss for the year/period, which is in turn primarily attributable to our cost of sales, administrative expenses, R&D expenses and selling expenses.
We recorded net losses in 2021, 2022 and 2023, and recorded adjusted net loss (non-IFRS measure) and net operating cash outflow during the Track Record Period.
Summary · p. 27
During the Track Record Period, we had funded our cash requirements primarily with capital contribution from shareholders and financing through the Pre-IPO Investments.
In addition, our net operating cash outflow in 2021 and 2022 amounted to RMB203.7 million and RMB50.0 million, respectively, primarily due to our initiatives to incentivize physician activity and to attract and develop a loyal customer base.
Summary · p. 16
Our net cash used in operating activities decreased significantly for the year ended December 31, 2022 as we gained greater flexibility in setting our customer pricing as we were able to negotiate more favorable procurement terms due to our increased business scale.
We had negative operating cash flows during the Track Record Period.
Financial Information · p. 504
We plan to improve our operating cash flows and reduce the net cash used in our operating activities.
Business · p. 385
Although we had negative operating cash flows during the Track Record Period, we believe we have sufficient working capital required for our operations based on our financial capabilities, including the investments from our Shareholders as well as loans and bank borrowings.
Our net cash used in operating activities was RMB14.0 million, RMB64.3 million and RMB99.3 million in 2021, 2022 and 2023, respectively.
Business · p. 276
To this end, we will require our sales management department to review sales forecasts and expected receivable conditions weekly, clarify reasons for non-payment and promptly follow-up on their resolutions.
Business · p. 276
In the future, we expect to improve our net operating cash outflows position by taking advantage of (1) our continuous revenue growth fueled by our growing customer base and expanding product and service offerings, (2) our improved operating leverage as we expect our revenue growth to exceed the increase in expenses gradually, (3) our budget control and optimization of operating expenses, and (4) our improved working capital.
Net cash (used in)/generated from operating activities | (59,187) | 105,791 | (33,337) | (42,437) | 45,739
Financial Information · p. 441
We carefully managed our working capital and changes in working capital did not account for a material portion of cash used/generated during operations.
Summary · p. 27
However, the balance of customer accounts and payables to merchants and other customers are held by the Company on behalf of customers and not for our general use.
Our net cash used in operating activities was approximately RMB57.4 million for the nine months ended 30 September 2023.
Financial Information · p. 283
(a) changes in trade and other receivables of approximately RMB118.7 million, which was mainly attributable to the increase in prepayments to suppliers
Financial Information · p. 283
We plan to improve our net operating cash flow position in view of potential net operating cash inflows which we expect to generate.
In 2022 and the six months ended June 30, 2023, we recorded net operating cash outflow of RMB93.6 million and RMB130.8 million, respectively.
Summary · p. 1
We incurred net losses during the Track Record Period and net operating cash outflow in 2022 and the six months ended June 30, 2023, as we have been focusing on constructing and establishing our medical institutions and growing our business, and large initial investments is mandatory for hospital industry due to its heavy-asset nature.
Summary · p. 14
We successfully increased our net operating cash inflow from RMB50.6 million in 2020 to RMB151.2 million in 2021.
During the Track Record Period, we normally incurred net operating cash outflows during the first half of our financial year.
Financial Information · p. 336
The average percentage of initial project costs (excluding staff cost) to awarded contract value for our ICT integration projects which required initial project costs was approximately 58.9%, 55.7%, 70.6% and 64.0% for FY2020, FY2021, FY2022 and 6M2023, respectively.
Business · p. 225
In view of the liquidity requirement, especially in our ICT integration projects, we had to adopt a cautious approach in considering potential ICT integration projects which had a contract sum exceeding RMB20 million and involved significant initial project costs, and had to decline business opportunities in relation to projects with larger contract sum due to concerns in liquidity management.
Our net operating cash outflow in 2020, 2021 and 2022 and the six months ended June 30, 2023 was RMB75.2 million, RMB180.5 million, RMB523.1 million and RMB273.8 million, respectively.
Financial Information · p. 309
Meanwhile, we expect to record a substantial amount of net loss and net operating cash outflow in 2023, as we continue to invest in expanding our production volume, R&D activities as well as sales and marketing activities.
Summary · p. 15
During the Track Record Period, we had funded our cash requirements primarily with capital contribution from shareholders and financing through the Pre-IPO Investments.